Participate in Research

Clinical trials help find new methods for diagnosing, treating, managing and preventing Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease. Even the most promising scientific findings must first be proven to be safe and effective in clinical trials before they can be used as standard treatment.

Talk to your doctor to find a clinical trial that might be suitable for you or someone you care about. 

Participate in Research icons

Clinical studies needing patient participants: 

  • Persons from across Canada are being invited to participate in the IMAGINE research study. The IMAGINE Network is investigating the interactions between inflammation, microbiome, diet and mental health in patient with IBD (Crohn’s disease or ulcerative colitis) or irritable bowel syndrome (IBS). IMAGINE is also studying whether new therapies (fecal transplants, diet, probiotics, cognitive behaviour therapy) have the potential to transform the management of IBD and IBS and their associated mental health issues.
    You may be eligible to participate in this study if you have been diagnosed by your physician with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn’s disease, or are a healthy individual without gastrointestinal symptoms. Visit for more information and to find a recruitment site near you.

  • Drugs in Lactation Consortium
    The goal of the study is to learn about drug safety during breastfeeding. We measure drug levels in breast milk to understand how safe they are for babies, when they are exposed through breast milk. The study involves collection of small breast milk samples between two doses of your medication and filling out a short questionnaire.

    Who is eligible?

    All nursing mothers who are taking one or more drug(s) on the study priority list and are able to communicate in English (For inquiry about the priority list, please contact us.). 

    Contact: Sholeh Ghayoori 
    Phone: 416-813-7654, ext 205675

  • The Family Health Lab at University of Saskatchewan is currently conducting an online study looking at the relationship between emotions and IBD-related symptoms in teens with IBD.

    Who is eligible?
    Teens ages 14-18 who have been diagnosed with Ulcerative Colitis or Crohn's Disease who has a parent who will provide consent for the teen to participate.

    Contact: Lana McAleer
    Phone: 306-966-5616

    Teens and parents able to participate are eligible to enter a drawn for 1 of 3 $50 gift cards
  • The Pedi FETCh Research Trial (Pediatric Fecal Transplant for Ulcerative Colitis) is the first pediatric fecal transplant study for inflammatory bowel disease in Canada, and will be the first randomized controlled trial of fecal transplant in pediatric inflammatory bowel disease in the world. The trial is being lead by Dr. Nikhil Pai, and supported by the Division of Pediatric Gastroenterology and Nutrition at McMaster Children’s Hospital. Study collaborators include Dr. Christine Lee (Division of Infectious Disease at St. Joseph’s Hospital in Hamilton), and Paul Moayyedi (Division of Adult Gastroenterology at McMaster University), with support from the Farncombe Digestive Disease Research Institute at McMaster University.
    Site Investigators: Dr. N. Pai

    Contact: Jelena Popov, Research Coordinator
    Email: Jolene Popov at / Dr. Nikhil Pai at
    Phone: 905.521.2100, ext. 75637

  • The human body contains 10 bacterial cells for every human cell. This vast, largely unexplored bacterial community known as the microbiome, has been linked to gastrointestinal health and disease. In the case of IBD, it is thought that the immune system may be responding inappropriately to the microbiome. Therefore, it has been hypothesized that changing the microbiome may be an effective treatment for IBD.  One way to accomplish this is using Fecal Microbiota Transplantation (FMT). Fecal Microbiota Transplantation (FMT) is an innovative investigational treatment that has proven effective in the treatment of C. difficile infection. The purpose of this study is to determine whether FMT is similarly safe and effective in the treatment of mild-to-moderate Crohn’s disease. During FMT, a fecal preparation from a carefully screened, healthy stool donor is transplanted into the colon of the patient. There are multiple routes of administration (e.g., via colonoscopy, oral capsules). In this study we will use both.

    Patients will receive a total of 8 FMT/placebo treatments in the study.

    Patients receiving FMT will be assigned a single donor. The first will be given by colonoscopy at
    Week 0, followed by 7 others given by capsules taken by mouth each week.

    At Week 8, patients are unblinded and a follow up colonoscopy is performed.
    Patients who received initially randomized to placebo can go on to have FMT in the open label phase of the study.
    Who is eligible?

    Patients with mild to moderate Crohn’s disease
    Recruiting 126 patients at three Canadian centres (Edmonton, Calgary and Hamilton)

    Edmonton contact
    Dr. Dina Kao:
    Dr. Gina Vavek:
    Phone: 780-492-5313
    Calgary contact
    Dr. Humberto Jijon:
    Gurmeet Bindra:
    Phone: 403-210-7013 or 403-399-9790
    Hamilton Contact  
    McMaster University:
    Melanie Wolfe:

  • The Queen’s University Health Psychology research team is seeking individuals diagnosed with Inflammatory Bowel Disease to participate in an ethically cleared online study examining how both positive and negative variables may impact your quality of life. The study involves completing an online survey, and if you consent, it can be followed by 2 repeats of the survey one month apart (this is important to look at how things may change over time for you). You would complete all surveys over the course of 8 weeks.

    Who is eligible? 
    Must be at least 18 years of age and fluent in English.

    To learn more about this study, please click on the following link:

You may also search for clinical trials through the following sites:

Crohn’s and Colitis Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest